** Vaccine maker Moderna's MRNA.O shares fall 2.2% to $31.30 premarket
** Co reports Q4 loss of $2.91/share vs analyst est. of loss of $2.68/share, as per data compiled by LSEG
** MRNA posts Q4 revenue of $966 million, beating analysts' est. of $942.84 million
** Co says the decrease was mostly due to the earlier launch of its updated COVID-19 vaccine in the U.S., which shifted sales into the third quarter, but also due to lower international sales
** Stock fell ~67% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.